Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96JM2

UPID:
ZN462_HUMAN

ALTERNATIVE NAMES:
Zinc finger PBX1-interacting protein

ALTERNATIVE UPACC:
Q96JM2; Q5T0T4; Q8N408

BACKGROUND:
The Zinc finger protein 462, known for its interaction with PBX1, is a crucial nuclear factor in transcription regulation and chromatin organization. Its ability to regulate the expression of genes critical for stem cell pluripotency and differentiation, such as SOX2, POU5F1/OCT4, and NANOG, positions it as a key player in developmental biology. Furthermore, its role in preventing the heterodimerization of PBX1 and HOXA9 highlights its importance in gene expression regulation.

THERAPEUTIC SIGNIFICANCE:
Given its association with Weiss-Kruszka syndrome, characterized by a spectrum of congenital anomalies and developmental challenges, the study of Zinc finger protein 462 offers promising avenues for therapeutic intervention. The exploration of its functions and the mechanisms by which its variants contribute to disease phenotypes could lead to novel treatments for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.